Evaluation Of The Quality Of Life Of Patients With Chronic Heart Failure With Systoliс Dysfunction While Undergoing Treatment

Abstract

Currently, the parameters of the quality of life of patients have independent prognostic significance and are more accurate predictors of survival and the patient's condition during treatment than the general somatic status. The study included 225 patients with chronic heart failure (CHF) FC II-III by NYHA, after suffering Covid19, aged 64.5±3.4. The patients were divided into 4 groups. The first group - 52 patients with CHF, with reduced EF, who received sacubitril-valsartan (Uperio) 24/26 mg in the complex treatment, the second - 57 patients in the complex treatment received empagliflozin (Emaglyph), the third group - in the complex treatment received sacubitril-valsartan and empagliflozin (Emaglyph) – 56 patients, a separate group of 60 CHF patients who had not been ill with Covid19 and received standard therapy. The following questionnaire parameters were studied: physical limitations, symptoms, symptom severity, changes over time in symptoms, social limitations, self-care, quality of life. The average parameters in all groups before treatment were 42.5; 43.0; 42.1 in three groups respectively. The results of questionnaire have shown that the state of quality of life in patients with CHF is unsatisfactory. In the dynamics of therapy, we see a significant increase in rates among all examined groups, amounting to 56.5; 58.6; 65.7 points respectively. It should be noted that although the indicators are almost the same, but the group treated with empagliflozin has advantage in comparison with the group receiving Uperio and there is a more significant increase to 65.7 points in the group treated with a combination of sacabutril-valsartan and empagliflozin. In the group of CHF patients who did not have Covid-19 before treatment, the condition of patients also reached 45.4 points, which is still higher than in groups of patients who had Covid 19. In the dynamics of treatment in this group, the increase was 56.6 points, which nevertheless indicates a fairly good effect of the use of drugs sacabutril-valsartan and empagliflozin and their positive impact on quality of life were studied.